Mycelium Sona Biotech Profile
Key Indicators
- Authorised Capital ₹ 0.50 M
as on 08-01-2025
- Paid Up Capital ₹ 0.10 M
as on 08-01-2025
- Company Age 3 Year, 11 Months
- Last Filing with ROC 31 Mar 2024
About Mycelium Sona Biotech
The Company is engaged in the Life Sciences Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.50 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Valliappa Chockalingam, Muralidhar Rao, William Scott, and Two other members serve as directors at the Company.
- CIN/LLPIN
U01409KA2021FTC143780
- Company No.
143780
- Company Classification
Private Limited Foreign Company Incorporated In India
- Incorporation Date
04 Feb 2021
- Date of AGM
27 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Bangalore
Industry
Company Details
- LocationBangalore, Karnataka
- Telephone
- Email Address
- Website
- Social Media
Who are the key members and board of directors at Mycelium Sona Biotech?
Board Members (5)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Donald Brumley  | Director | 13-Aug-2021 | Current |
Valliappa Chockalingam  | Director | 04-Feb-2021 | Current |
| Muralidhar Rao | Director | 04-Feb-2021 | Current |
| William Scott | Director | 13-Aug-2021 | Current |
| Neville Fielke | Director | 13-Aug-2021 | Current |
Financial Performance of Mycelium Sona Biotech.
Enhance accessibility to Mycelium Sona Biotech's financial data by unlocking access to both Standalone and Consolidated balance sheets, Profit & Loss Statements, Ratios, Related Party Transactions, and additional relevant information.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets | |||||||
| Profit or Loss | |||||||
| Net Worth | |||||||
| EBITDA |
What is the Ownership and Shareholding Structure of Mycelium Sona Biotech?
Unlock access to Mycelium Sona Biotech's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Related Corporates (Common Directorship)
Sree Valliappa Textile Private LimitedActive 61 years 8 monthsValliappa Chockalingam is a mutual person
- Spinwell Valliappa Private LimitedActive 42 years 8 months
Valliappa Chockalingam is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Mycelium Sona Biotech?
Mycelium Sona Biotech has a workforce of 11 employees as of Apr 07, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Mycelium Sona Biotech, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Mycelium Sona Biotech's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.